Analytical Data
-
Gene name
ICAM-1/CD54
- Application
-
Alternative Names
CD54; BB2; P3.58; Human Rhinovirus Receptor; Major group rhinovirus receptor
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by reducing SDS-PAGE.
-
Uniprot
P05362
-
Expression Region
Gly41~Gly464
-
Molecular Weight
45kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ICAM-1 (Intercellular Adhesion Molecule-1), also known as CD54, is a crucial adhesion molecule expressed on endothelial cells and immune cells, playing a significant role in inflammation and immune response. Its primary function is to facilitate the binding of leukocytes to endothelial cells, which is critical during immune responses and the migration of immune cells to sites of inflammation. Dysregulation of ICAM-1 can result in various pathological conditions, including chronic inflammation, autoimmune diseases, and tumor progression. The study of recombinant ICAM-1/CD54 proteins has gained attention in recent years due to their potential applications in therapeutic interventions and vaccine development. Recombinant forms of this protein allow researchers to investigate its structural and functional properties in detail, providing insights into its role in immune mechanisms. Moreover, understanding how ICAM-1/CD54 interacts with other molecules, such as ligands on lymphocytes, can pave the way for novel therapeutic strategies aimed at modulating immune responses. These recombinant proteins are also valuable tools for studying the molecular basis of adhesion and signaling processes involved in immune cell activation. Overall, the research on ICAM-1/CD54 recombinant proteins is significant in elucidating the complexities of immune interactions and may lead to innovative approaches for treating inflammatory diseases and enhancing vaccine efficacy.
